Shares of biotechnology company Amylin Pharmaceuticals Inc. jumped Monday as IMS Health data showed an uptick in prescriptions of its beleaguered diabetes treatment Byetta.
CAMBRIDGE, Mass.----Alkermes, Inc. today announced positive preclinical results for its proprietary small molecule candidate, RDC-1036, which emerged from a library of novel opioid modulators.
NEW YORK (AP) - Shares of biotechnology company Amylin Pharmaceuticals Inc. jumped Monday as IMS Health data showed an uptick in prescriptions of its beleaguered diabetes treatment Byetta.
Alkermes announced positive preclinical results for its proprietary small molecule candidate, RDC-1036 Co announces positive preclinical results for its proprietary small molecule candidate, RDC-1036,
Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Lazard Capital Markets on Tuesday, November 18, 2008 at 3:40 p.m. EST. The presentation will be
Obama wins, futures move lower. European markets and U.S. futures traded lower overnight (see data below) as investors, perhaps, emerged from their election-induced elation and began thinking about the mess President-elect Barack Obama will inherit. Still, analysts at BNP Paribas were optimistic about the leadership change: "Obama has strong personal, political and institutional assets... his program is relatively well adapted to America's needs, in the fields of energy, healthcare, social cohesion and competitiveness." UBS analysts said winners of an Obama victory would be hospitals and nursing-home operators, life-sciences, natural gas firms, solar...
Traditionally, growth is the last thing investors should consider when formulating recession-oriented investing strategies. According to the stereotype, growth stocks tend to be over priced and over hyped, and hence most vulnerable to steep declines during market downturns. Clearly, we've all seen many instances in which events conformed to that image. But it's not growth per se that's the problem. Those who focus on the basics rather than glamour can find an ample number of growth strategies that are viable even in bear markets.
Archer Daniels Midland Co. (ADM) - Knock’em dead profits at grain processor, ADM beat expectations of 72 cents per share with $1.61 per share. Shares jumped 16% to $24.50. The company processed enough soybeans and handled enough grain to add just over a billion dollars to the bottom line in the third quarter. That compares to $441 million one year ago. Having watched its shares slump in line with sliding commodity prices by as much as 55% year-to-date, option traders couldn’t act fast enough to buy calls in the January 25 line today where some...
I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals (AMLN). This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly due to its diabetes drug Byetta. Which is the cause of the recent ruckus - on Monday the FDA warned that Byetta might be linked to 6 severe cases of pancreatitis.
U.S. health regulators warned of more cases of dangerous pancreas inflammation in patients taking
What a crazy week, right? Monday, Amgen (AMGN) had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan (ELN) and Wyeth (WYE) released the big Alzheimer's drug test results.
Wednesday, those two stocks tanked. Thursday morning, Bristol-Myers Squibb (BMY) said it wants to buy all of ImClone Systems (IMCL). Thursday afternoon, Biogen Idec (BIIB) and Elan revealed two new brain infection cases from their multiple sclerosis drug Tysabri. And then...
There seem to be many reasonably priced plays within biotech at the present time, which is a very good thing in a soft market such as the one we have been slogging through. Zacks senior biotech analyst Grant Zeng, CFA was on hand to give us his perspective on the sector recently.
Do you expect 2008 will be a strong year for biotech stocks?
Shares of Amylin (AMLN) ambled higher yesterday after two destructive trading days.
First, last Friday, Novo Nordisk (NVO) put out a press release saying preliminary data show its drug works better than Byetta. And then, Monday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.
Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's (PFE) oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold. But Eli Lilly (LLY) is the biggest dollar and percentage gainer on an otherwise weak pharma tape.
Yesterday morning Cowen and Company big pharma analyst Steve Scala upgraded Eli Lilly to Outperform (euphemism for Buy), Novartis (NVS) to Outperform and downgraded Bristol-Myers Squibb (BMY) to Neutral (euphemism for Hold). His call definitely seems to be moving LLY and...
Alkermes , Inc . ( NASDAQ : ALKS ) today announced positive preclinical results for its proprietary small molecule candidate , RDC - 1036 , which emerged from a library of novel opioid modulators.The ...
Alkermes announced positive preclinical results for its proprietary small molecule candidate , RDC - 1036 Co announces positive preclinical results for its proprietary small molecule candidate ...
Alkermes is a biotechnology company focused on drug development process from a patient - centric perspective , beginning with a thorough understanding of the challenges patients face on a day ...
CAMBRIDGE , Mass . - - ( BUSINESS WIRE ) - - Nov 11 , 2008 - Alkermes , Inc . ( NASDAQ : ALKS ) announced today that its corporate presentation will be webcast live by Lazard Capital Markets ...
, , ) announced today that its corporate presentation will be webcast live by Lazard Capital Markets on Tuesday , November 18 , 2008 at 3 : 40 pm EST.The presentation will be webcast from the ...
Here are the results for today's unusual stock volume scan.The scan looks at the previous day's volume and compares it to the recent average volume.It then sorts the stocks based on those that ...
BANGALORE ( Reuters ) - Biotechnology company Alkermes Inc reported a second - quarter profit , helped by higher sales of its schizophrenia drug Risperdal Consta , but cut its fiscal 2009 revenue ...
( RTTNews ) - Alkermes Inc . ( ALKS : News ) reported second quarter net earnings of $1.70 million or $0.02 per share , compared to $7.7 million or $0.07 per share in the same quarter of last ...
NEW YORK (MarketWatch) -- Airline stocks opened lower Thursday, following the wider market, and on fears of fewer passengers as the broader economy slumps. At last check, the Amex Airline Index shed about 1% to 17.20 point with all but one of its 13 components trading in the red. Shares of United parent UAL Corp. lost 6.5% to $8; US Airways dropped 7% to $4.55; and American parent AMR Corp. fell 6.6% to $6.40. Climbing were shares of Ryanair , up 2.6% to $21.32. Crude for December delivery, meanwhile, dropped $3.71 to $49.91 a barrel in...
NEW YORK (MarketWatch) -- A sharp drop in the number of business travelers for September looks bad for the airline industry's revenue growth, according to data released Wednesday from the International Air Transport Association. In September, the number of business people flying fell 8% from a year ago, coinciding with a steep decline in confidence among manufacturers in Europe, Japan and the U.S., as well as the bankruptcy of Lehman Brothers, which contributed to a loss of a travelers from the financial sector. In August, business travel fell 1.5%. "With further declines in volumes likely in the months ahead, premium...
NEW YORK (MarketWatch) - Airline stocks looked weak early Wednesday as oil prices stayed flat ahead of the latest U.S. petroleum supplies data due later in the session. At last check, the Amex Airline Index was down less than 1% at 19.68 points with all but three of its 13 components trading down. Crude for December delivery, which expires at the end of trading on Thursday, dropped 49 cents to $53.90 a barrel in electronic trading. Shares of all the major carriers were off, with US Airways down 3.5% to $5.87, and AMR Corp. , UAL Corp....
NEW YORK (MarketWatch) -- The U.S. government said Tuesday it plans to expand last year's move to open military airspace during the busy Thanksgiving travel holiday to include areas over the Midwest, Southwest and the West Coast. "Will traveling home for the holidays be 'It's A Wonderful Life,' or will it be 'The Nightmare Before Christmas,' asked President George Bush in a speech to the Department of Transportation, announcing the plan. "We innovated last year to ease the travel; it worked, and now we're expanding that innovation this year," he said. Further, the Federal Aviation Administration and the Transportation Security...
NEW YORK (MarketWatch) -- Airline stocks declined early Tuesday with the wider market and as oil prices stayed flat. At last check, the Amex Airline Index lost a fraction to 19.54 points with five of its 13 components trading down. The Dow Jones Industrial Average was off several points to 8,269, and crude oil for December delivery was up 22 cents to $55.16 a barrel in electronic trading. Major carriers were mixed, with AMR Corp. and Continental each off about 1%, while UAL and US Airways each declined more than 2%. Climbing were shares of...
NEW YORK (MarketWatch) -- Airline stocks were mixed early Monday as a decline in the price of oil helped to offset some recession jitters in the wider market. At last check, the Amex Airline Index rose less than 1% to 19.49 points with all but five of its 13 components in the green. December crude futures fell 74 cents to $56.30 a barrel in electronic trading after finishing down 6.6% for the week last Friday. But Monday saw fresh concern over a global-wide recession due to lukewarm statements at the G20 meeting over stabilizing the financial system. The Dow...
Stocks 
